Repare <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Initial Data from Phase 1 LIONS Trial of First-in-Class PLK4 Inhibitor RP-1664 in Advanced Solid Tumors
Repare Therapeutics Inc. has announced that it will present initial topline safety, tolerability, and early efficacy data from its Phase 1 LIONS clinical trial at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The LIONS trial (NCT06232408) is a first-in-human, multicenter, open-label Phase 1 study evaluating RP-1664, a potential first-in-class, highly selective oral PLK4 inhibitor, as monotherapy in adult and adolescent patients with TRIM37-high solid tumors. The data will be shared in a poster presentation on October 25, 2025, and a copy of the poster will be available on the Repare Therapeutics website at the start of the session.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013080571) on October 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。